When does Telix report earnings and why does it matter for TLX.AX stock?

Telix reports around **20 Jan 2026**. The earnings release will update revenue, cash flow and R&D spend. For TLX.AX stock, management commentary on commercial uptake and trial timelines is a near-term catalyst that can move valuation materially.

What is Meyka AI’s current view and grade for TLX.AX stock?

Meyka AI rates TLX.AX **68.47** out of 100 (Grade B, HOLD). The grade weighs benchmark and sector comparisons, financial growth, key metrics and consensus. Grades are informational and not investment advice.

What price targets and forecasts should investors consider for TLX.AX stock?

Analysts have a target near **A$21.00** per MarketBeat, while Meyka AI’s yearly forecast is **A$13.28** and monthly projection **A$16.02**. Forecasts vary widely and depend on clinical and reimbursement outcomes.

What are the main risks that could hurt TLX.AX stock after earnings?

Primary risks are negative clinical trial results, delayed regulatory approvals, weak reimbursement decisions and cash runway pressure. Any of these could reduce revenue forecasts and push the stock lower.

AU Stocks

TLX.AX Telix Pharmaceuticals ASX A$11.48 17 Jan 2026: earnings on 20 Jan may reset outlook

ByHuzaifa Zahoor January 17, 2026January 17, 2026

TLX.AX stock is trading at A$11.48 intraday on the ASX with volume at 3,579,404.00 ahead of an earnings release scheduled for 20 Jan 2026. Investors will watch revenue growth, R&D spend and cash flow after Telix’s clinical updates. The market is pricing uncertainty: the share is down 55.50% year-on-year but remains in focus because clinical readouts and regulatory steps can swing valuation rapidly.